Discovery
Discovery research is fundamental to our mission of sustainably delivering meaningful new drugs to patients.
We have robust internal capabilities across all of the key scientific disciplines, including medicinal chemistry, cell biology, biochemistry, pharmacology and molecular pathology. More importantly, we successfully integrate these disciplines to rapidly identify drug candidates and assess their potential utility.
Our discovery teams have been highly productive. Our first three clinical candidates – which have broad potential applicability in the fields of oncology and pain – emerged from our internal research efforts. Behind these programs, we have several innovative projects in earlier stages of development, encompassing emerging targets in fields such as cancer metabolism, apoptosis and protein homeostasis. We are drawn to targets that have the potential to represent fundamentally new approaches to how disease is treated, and where we can use our scientific capabilities to identify differentiated drug candidates with clearly-defined development paths. And because discovery doesn’t stop when a drug candidate is identified, we also deploy our discovery capabilities to better understand which populations, or subpopulations, of patients may benefit most from our products.
We are committed to maintaining our core discovery capabilities, as they are critical to our future success.